On Sunday, July 7, 2024, we exhibited at the Institute for Predictable Osseointegration in Implantology (IPOI), a non-profit organization (NPO) event held in Fukuoka City.
Read more
Mediplus Pharma, Inc. presented the safety and efficacy of its proprietary ingredient, ozonized glycerin (Novel Glycerin Compound), in formulations for atopic dermatitis at the 123rd Annual Meeting of the Japanese Dermatological Association. The conference was held from June 6 to June 9, 2024, at the Kyoto International Conference Center.
For more details on the press release, please visit here.
https://prtimes.jp/main/html/rd/p/000000015.000079724.html
Mediplus Pharma, Inc. (CEO: Kenji Ito, HQ: Shibuya, Tokyo) presented on the multifunctionality and application of its proprietary ingredient, ozonized glycerin (Novel Glycerin Compound), as biomaterials at the 12th World Biomaterials Congress (WBC), held over six days from May 26 to 31, 2024, in Daegu, South Korea.
For more details on the press release, please visit here.
https://prtimes.jp/main/html/rd/p/000000013.000079724.html
We are pleased to announce our participation in the 16th Academic Conference of the Non-Profit Organization (NPO) Institute for Predictable Osseointegration in Implantology, which will be held on Sunday, July 7, 2024, in Fukuoka City.
We aim to introduce our unique ingredient , ozonized glycerin, which is expected to have beneficial effects in dental medicine, particularly in the surgical field. This event will be an opportunity for dental professionals, especially those active in the surgical domain, to learn about our product.
At our exhibition booth, attendees will be able to experience ozonized glycerin and deepen their understanding through explanations from the developers.
A presentation on the safety and efficacy evaluation of atopic dermatitis was held at the American Academy of Dermatology (AAD) in March, and it has been featured in the “Health Industry Distribution Newspaper” issue 1111 (published on 4/25).
We plan to continue utilizing Novel Glycerin Compounds (ozonized glycerin) extensively in the business ventures undertaken by our group companies in the future.
For the AAD presentation release, please visit:
We are pleased to announce the launch of our new patent information page.
PATENT
This page provides disclosures of the patent registration information that we possess. Interested parties are invited to explore this resource to better understand it further.
We are pleased to announce that Mediplus Pharma, Inc. has received RSPO supply chain certification (Model: Mass Balance, MB).
RSPO, officially known as the Roundtable on Sustainable Palm Oil, is a non-profit organization comprised of seven stakeholders involved in palm oil.
The Supply Chain Certification System (SC certification) is a system that certifies that the requirements are met at each stage of the manufacturing, processing, and distribution process for products made with Certified Palm Oil. Organizations that have ownership of SC certified products in each process until the final product is made are eligible for certification.
Cultivating sustainability for people and planet – Roundtable on Sustainable Palm Oil (RSPO)
By acquiring the Supply Chain Certification, a universal certification standard, we are able to participate more closely in the sustainable production of palm oil.
Hopefully, we should consider SDGs fully and will ensure transparency in business and consequently environmental protection of the entire planet. As a company with such intention, we will make effective use of this certification and continue to make untiring efforts to achieve our MISSION and VISION, “Contribute to a society where humans, animals, and plants can lead healthy lives”.
Mediplus Pharma, Inc. had celebrated its 50th anniversary on March 13.
We would like to express our sincere gratitude for your support and loyal patronage.
We have consistently conducted research and development on the theme of “ozone”, a substance that can contribute to the global environment since our founding.
Currently, our business domain is based on the cosmetics business for skin care, and we will continue to develop with the aim of developing pharmaceuticals for humans and animals.
All of our employees will continue to make further efforts to respond to your kindness and expectations.
Your continued support will be highly appreciated.
Mediplus Pharma Corporation (CEO: Kenji Ito, Headquarters: Shibuya, Tokyo) presented two academic papers about ozonized glycerin (glycenergy)*, a novel glycerin compound, at the international cosmetics researchers conference, IFSCC 2022 @ London (International Federation of Societies of Cosmetic Chemists Annual Congress, September 19-22, 2022).
Read more
Mediplus Pharma Inc. (Representative Director Kenji Ito, head office: Shibuya-ku, Tokyo) announces that the article on Mediplus Pharma’s patented ingredient: ozonized glycerin titled “Ozonized glycerin (OG)-based cosmetic products lighten age spots on human facial skin” was accepted into the American “Journal of Cosmetic Dermatology,” and used as the cover of the July 2022 issue of “Journal of Cosmetic Dermatology.”
